	US 12,296,018 B2
	Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
Ashutosh Chilkoti, Durham, NC (US); and Parisa Yousefpour, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Appl. No. 16/964,832
Filed by Duke University, Durham, NC (US)
PCT Filed Jan. 25, 2019, PCT No. PCT/US2019/015176 § 371(c)(1), (2) Date Jul. 24, 2020, PCT Pub. No. WO2019/147954, PCT Pub. Date Aug. 1, 2019.
Claims priority of provisional application 62/622,249, filed on Jan. 26, 2018.
Prior Publication US 2021/0060171 A1, Mar. 4, 2021
Int. Cl. A61K 47/64 (2017.01); A61K 31/704 (2006.01); A61K 47/65 (2017.01); A61P 35/00 (2006.01)

CPC A61K 47/64 (2017.08) [A61K 31/704 (2013.01); A61K 47/65 (2017.08); A61P 35/00 (2018.01)]

10 Claims

1. A composition comprising:

an albumin binding domain (ABD) consisting of the amino acid sequence of SEQ ID NO:1;

a linker coupled to the ABD at the C terminus of the ABD, the linker consisting of the amino acid sequence of (CGG)_z(SEQ ID NO:3), wherein z is selected from the group consisting of 1, 2, 3, and 4, wherein if there is more than one sequence of CGG, the amino acid sequence, wherein the N terminus cysteine of the linker is coupled to the C terminus ABD is repeated sequentially;

one or two chemotherapeutic molecules selected from the group consisting of doxorubicin, paclitaxel, and docetaxel;

wherein the one or two chemotherapeutic molecules are individually coupled to a cysteine thiol of the amino acid sequence of CGG through a 3,3′-N-[ε-maleimidocaproic acid] hydrazide moiety; and

wherein the composition has an aqueous solubility of up to 4 mg of molecule equivalent/mL.